TLDR
- IBRX slides 4.91% to $6.98 despite strong Phase 2 glioblastoma trial results
- ImmunityBio stock drops after resistance rejection despite positive GBM data
- IBRX falls sharply as traders ignore promising GBM trial survival outcomes
- ImmunityBio shares retreat even as GBM immunotherapy results impress
- IBRX dips 4.91% despite encouraging immune recovery and survival data
ImmunityBio (IBRX) stock fell to $6.98, down 4.91%, after a sharp rejection near the $7.60 to $7.70 zone. The decline reflected strong intraday selling pressure, although the company released encouraging clinical trial updates. ImmunityBio, Inc. remained in focus as traders balanced technical weakness against improving treatment outcomes.
ImmunityBio, Inc., IBRX
The price drop followed a fast reversal from resistance, which triggered short-term bearish momentum across the session. ImmunityBio, Inc. reported updated Phase 2 results from its QUILT-3.078 study in recurrent glioblastoma patients. The announcement introduced renewed attention to the company’s immunotherapy pipeline and longer-term clinical potential.
Phase 2 trial shows durable survival outcomes
ImmunityBio, Inc. enrolled 23 patients with recurrent or progressive glioblastoma who failed standard therapies. Nineteen patients remained alive as of January 22, 2026, while four deaths occurred during the evaluable follow-up period. The study continued to demonstrate survival outcomes that exceeded historical expectations for this disease group.
Fourteen patients provided sufficient data for the efficacy analysis, which included 139 administered combination immunotherapy doses. The median follow-up reached six months, while median overall survival remained unreached during the current reporting window. ImmunityBio, Inc. sustained momentum toward expanded randomized trials in both first-line and second-line settings.
Single-patient IND data also supported durability, as seven first-line patients remained alive at the time of reporting. The company confirmed ongoing preparations for larger randomized trials covering broader disease stages. As a result, ImmunityBio, Inc. strengthened its clinical development roadmap in high-need oncology markets.
Immune recovery highlights chemotherapy-free potential
Patients entered the study with significant immune compromise from prior radiation and chemotherapy exposure. The baseline absolute lymphocyte count averaged approximately 900 cells per microliter, reflecting profound lymphopenia. Treatment supported lymphocyte recovery without requiring chemotherapy, marking a notable therapeutic development.
The immunotherapy combination maintained immune competence while supporting extended survival in advanced disease cases. Clinical observations included a near complete response with survival exceeding twelve months following documented progression. Accordingly, ImmunityBio, Inc. demonstrated potential for reshaping recurrent glioblastoma treatment strategies.
The company plans to present expanded findings at the Stand Up to Cancer Glioblastoma Innovation Scientific Summit on January 31, 2026. This presentation will detail immune agonist combinations and the broader ImmunityBio Bioshield therapeutic approach. Thus, ImmunityBio, Inc. continues to advance immunotherapy research despite ongoing market volatility.
Market reaction and technical outlook
ImmunityBio failed to sustain momentum after testing resistance, which reinforced near-term bearish structure. The stock showed weak recovery attempts following the intraday selloff, while volume remained elevated. Consequently, technical indicators continued to reflect selling pressure despite favorable clinical developments.
The pullback followed several sessions of consolidation, which had previously supported upside testing attempts. Traders reacted swiftly to resistance rejection, which triggered a rapid downward move. ImmunityBio, Inc. remained under short-term pressure while longer-term fundamentals stayed constructive.
Future performance will depend on sustained clinical progress, regulatory advancement, and market risk appetite. The company continues executing its immunotherapy development strategy across oncology indications. ImmunityBio, Inc. remains positioned at the intersection of clinical innovation and market volatility.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
